U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07769359) titled 'Bioequivalence and Adhesion of a Rotigotine Patch in Healthy Subjects' on Aug. 07.
Brief Summary: This study was intended to demonstrate bioequivalence of the Amarin's Rotigotine patch respect to Neupro, (RLD), as well as non-inferiority in adhesion, when tested at a dose of 2 mg/24h in healthy subjects of both sexes. Local and systemic adverse events were also monitored and reported. Worn patches were recovered and analysed to compare residual drug.
Study Start Date: Dec. 04, 2025
Study Type: INTERVENTIONAL
Condition:
Bioequivalence
Adhesion
Adverse Effects
Intervention:
COMBINATION_PRODUCT: Rotigotine Transdermal Delivery Sy...